JP2021514195A - 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療 - Google Patents

変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療 Download PDF

Info

Publication number
JP2021514195A
JP2021514195A JP2020544431A JP2020544431A JP2021514195A JP 2021514195 A JP2021514195 A JP 2021514195A JP 2020544431 A JP2020544431 A JP 2020544431A JP 2020544431 A JP2020544431 A JP 2020544431A JP 2021514195 A JP2021514195 A JP 2021514195A
Authority
JP
Japan
Prior art keywords
seq
nucleic acid
mutant
acid sequence
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020544431A
Other languages
English (en)
Japanese (ja)
Inventor
カナガ・サバパシー
Original Assignee
シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド filed Critical シンガポール・ヘルス・サービシーズ・ピーティーイー・リミテッド
Publication of JP2021514195A publication Critical patent/JP2021514195A/ja
Priority to JP2023080165A priority Critical patent/JP7648675B2/ja
Priority to JP2025034711A priority patent/JP2025093992A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020544431A 2018-02-21 2019-02-21 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療 Pending JP2021514195A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023080165A JP7648675B2 (ja) 2018-02-21 2023-05-15 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療
JP2025034711A JP2025093992A (ja) 2018-02-21 2025-03-05 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201801432S 2018-02-21
SG10201801432S 2018-02-21
PCT/SG2019/050099 WO2019164451A1 (en) 2018-02-21 2019-02-21 Cancer therapeutic targeting using mutant p53-specific sirnas

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023080165A Division JP7648675B2 (ja) 2018-02-21 2023-05-15 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療

Publications (1)

Publication Number Publication Date
JP2021514195A true JP2021514195A (ja) 2021-06-10

Family

ID=67687981

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020544431A Pending JP2021514195A (ja) 2018-02-21 2019-02-21 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療
JP2023080165A Active JP7648675B2 (ja) 2018-02-21 2023-05-15 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療
JP2025034711A Pending JP2025093992A (ja) 2018-02-21 2025-03-05 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023080165A Active JP7648675B2 (ja) 2018-02-21 2023-05-15 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療
JP2025034711A Pending JP2025093992A (ja) 2018-02-21 2025-03-05 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療

Country Status (8)

Country Link
US (1) US12508277B2 (enExample)
EP (1) EP3755802A4 (enExample)
JP (3) JP2021514195A (enExample)
KR (1) KR102741498B1 (enExample)
CN (1) CN111727254B (enExample)
CA (1) CA3090220A1 (enExample)
SG (1) SG11202007450XA (enExample)
WO (1) WO2019164451A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3090220A1 (en) 2018-02-21 2019-08-29 Singapore Health Services Pte Ltd Cancer therapeutic targeting using mutant p53-specific sirnas
EP4077370A4 (en) * 2019-12-17 2024-02-28 The Johns Hopkins University MANA BODY TARGETING TUMOR ANTIGENS AND METHODS OF USE
CN115820636B (zh) * 2022-09-02 2024-06-11 华南农业大学 靶向TP53基因的sgRNA及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215497A1 (en) * 2001-11-09 2005-09-29 Annick Harel-Bellan Inhibitor oligonucleotides and their use for specific repression of a gene

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3090220A1 (en) 2018-02-21 2019-08-29 Singapore Health Services Pte Ltd Cancer therapeutic targeting using mutant p53-specific sirnas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050215497A1 (en) * 2001-11-09 2005-09-29 Annick Harel-Bellan Inhibitor oligonucleotides and their use for specific repression of a gene

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Allele-specific silencing of mutant p53 attenuates dominantnegative and gain-of-function activities", ONCOTARGET, 2015年, JPN6022047656, pages 1 - 15, ISSN: 0005102819 *

Also Published As

Publication number Publication date
SG11202007450XA (en) 2020-09-29
CN111727254B (zh) 2024-12-17
JP7648675B2 (ja) 2025-03-18
EP3755802A1 (en) 2020-12-30
US12508277B2 (en) 2025-12-30
WO2019164451A8 (en) 2020-11-26
CA3090220A1 (en) 2019-08-29
JP2023096009A (ja) 2023-07-06
CN111727254A (zh) 2020-09-29
WO2019164451A1 (en) 2019-08-29
KR20200123165A (ko) 2020-10-28
EP3755802A4 (en) 2021-11-17
US20200397813A1 (en) 2020-12-24
KR102741498B1 (ko) 2024-12-11
JP2025093992A (ja) 2025-06-24

Similar Documents

Publication Publication Date Title
Yang et al. Sp1-mediated microRNA-182 expression regulates lung cancer progression
JP6414886B2 (ja) 抗癌治療に用いられる長鎖非コードｒｎａ
US11471477B2 (en) Methods for treating triple-negative breast cancer
JP7648675B2 (ja) 変異Ｐ５３特異的ｓｉＲＮＡを使用した標的癌治療
JP7406278B2 (ja) 腫瘍マーカー及び治療ターゲットとしての長鎖ノンコーディングｒｎａ ｌｅｔｎ
JP5341081B2 (ja) 肝細胞癌処置用医薬組成物および医薬キット
Zhou et al. miR-200b/c-RAP1B axis represses tumorigenesis and malignant progression of papillary thyroid carcinoma through inhibiting the NF-κB/Twist1 pathway
JP2016064989A (ja) 癌を治療するための医薬組成物、およびｐｄ−１阻害剤による治療に対する感受性を評価する方法
JP7610195B2 (ja) Ｔｕｔ４／７発現調節因子を含む癌予防又は治療用薬学的組成物
US11118182B2 (en) Modulators of human KAI1 metastasis suppressor gene, methods and uses thereof
Zhang et al. Blockade of proliferation and migration of gastric cancer via targeting CDH17 with an artificial microRNA
JP2007530431A (ja) 膵臓癌を治療するための組成物および方法
JP2006519009A (ja) 細胞増殖を阻害する組成物および方法
US7999089B1 (en) RNA aptamers and the uses thereof
Kasashima et al. Discrimination of target by siRNA: designing of AML1–MTG8 fusion mRNA-specific siRNA sequences
WO2020198488A1 (en) Therapeutic targets for oncogenic kras-dependent cancers
KR20200069185A (ko) nc886 및/또는 PKR 저해제를 포함하는 항암 보조제, 및 암 치료를 위한 약물의 정보 제공 방법
JP2020045303A (ja) 癌細胞における免疫チェックポイント因子の発現抑制剤及び癌治療用医薬組成物
Lee The Contribution of MicroRNAs to RYBP Silencing in Glioblastoma Multiforme
JP2009516823A (ja) Ｓａｔｂ１：形態形成および腫瘍転移の決定因子
Zhou et al. LARP6 induces sphingolipid metabolism imbalance to suppress colorectal cancer metastasis by post-transcriptional regulation
Rajković Functional significance of DHX38 in pre-mRNA splicing and its role in the mechanism of retinitis pigmentosa
WO2022241165A2 (en) Compositions and methods of use for mutated hotair in the treatment of cancers
CN116617245A (zh) Utp11抑制剂及其在肿瘤抑制中的用途
CN113913513A (zh) 人dsn1基因的用途及相关产品

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230710